skip to Main Content

Newark, CA, January 28, 2019 – FlemingMartin is pleased to announce that Revance Therapeutics (NASDAQ: RVNC), a pioneering biotechnology company focused on the development and commercialization of botulinum toxin products for cosmetic and therapeutic applications, has hired Pat Kesslak to be their new Senior Director of Clinical Development for the Adult Upper Limb Spasticity Program.

Mr. Kesslak brings excellent experience to Revance from more than 15 years spent with ACADIA Pharmaceuticals, Elan Pharmaceuticals, Allergan, and Amgen. Over his career in Clinical Research and Development, Mr. Kesslak has focused on multiple therapeutic areas and CNS products, including Botox for the treatment of Upper Limb Spasticity and Lower Limb Spasticity at Allergan.

Mr. Kesslak holds a Ph.D. from Texas Christian University, an M.S. from Northwestern State University, and an undergraduate degree from Saint Francis College.

Revance Therapeutics (NASDAQ: RVNC) is a pioneering biotechnology company committed to the advancement of remarkable science. The Company is poised to enter, and potentially redefine, the neuromodulator aesthetic and therapeutic product categories. Revance’s proprietary peptide technology, when combined with active drug molecules, may help address current unmet needs in dermatology, neurology, and musculoskeletal disorders.

 

FlemingMartin is a leading retained executive search firm with offices in Northern and Southern California. FlemingMartin partners with Boards, Private Equity Firms, and CEOs to build successful execution-focused management teams. The Firm’s principals are trusted advisors and business partners who enable companies to gain powerful, far-reaching, and lasting contributions from their executive-level human capital.

Back To Top